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Abstract - It is well known that breast tumors which are estrogen positive ER(+) are more likely to respond to hormone 
therapy. However, a certain percentage of ER(+)/PR(+) tumors do not respond to this therapy. Identification of the 
second estrogen receptor, named estrogen receptor beta (ERβ), as well as the existence of numerous isoforms/splice 
variants of both ERα and ERβ, suggests that a complex regulation of estrogen action exists. In this study, we analyzed 
the expression ratio of ERβ1 isoform and ERβΔ5 splice variant mRNAs, and its correlation with ER/PR status by 
quantitative RT-PCR and clinical and histopathological parameters. We found that the relative proportion of ERβΔ5 in 
the total ERβ1 transcript “pool” inversely correlates with the PR level (ρ = -0,359, p< 0,003, Spearman). It may be that 
the ERβΔ5 variant modulates the ERα activity of downstream targets. In addition, we suggest that the determination of 
the expression profiles of ERα and ERβ isoforms and splice variants in the defined groups of patients are necessary for 
elucidating their involvement in endocrine resistance.  
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INTRODUCTION 
The estrogen receptor (ER) status of a breast 
tumor (expressed as + or – status) is a well-
accepted predictor of the response to hormone 
therapy. In addition, the progesterone receptor 
(PR), the downstream marker of functional ER 
signaling, is measured in breast cancer (BC) 
biopsies and surgical samples. Two receptors for 
estrogen exist: ERα and ERβ which are encoded by 
two different genes (ESR1 and ESR2) (Enmark 
1997; Menasce 1993). The presence of numerous 
isoforms/splice variants of both ERα and ERβ 
suggests complex regulation of estrogen action. 
The exact biological significance of isoforms and 
the splice variants of both ERα and ERβ receptors 
is still unclear but it seems that their existence may 
regulate the response to estrogen. Both ESR1 and 
ESR2 genes have a complex organization of mul-
tiple promoters and differential splicing in the 5’-
UTR region (Lewandowski 2002). Exon deletions 
or duplications are a second mechanism that 
potentially generates changes in the open reading 
frame and, accordingly, leads to different forms of 
proteins (Bollig 2000; Poola 2002a). In addition, 
five ERβ isoforms (designated as ERβ1 - ERβ5) 
originate by alternative usage of the eighth coding 
exon (Moore 1998; Ogawa 1998). It has been 
shown that the expression of ERα increases during 
the process of carcinogenesis, but the expression 
of ERβ seems to decrease (Bardin 2004). The 
estrogen receptor β is under intensive inves-
tigation and its role in BC appears to be of ad-
ditional predictive value. It is reasonable to 
propose that the ER/PR status should now include 
both ERα and ERβ receptors together with some of 
their isoforms and functionally active splice 
variants, as well as the PR isoforms A and B.  258 VESNA  MANDUŠIĆ  ET AL. 
In this study the expression levels of ERβ1 
isoform mRNA, which is considered as the wt form 
of the receptor β, and ERβΔ5 mRNA (splice variant 
without 5
th exon) were measured. In order to 
investigate if the ratio of ERβ1 and the splice va-
riant ERβΔ5 is related to clinical and histopatho-
logical parameters, as well as to ERα/PR status, we 
analyzed their expression by the method of quanti-
tative RT-PCR, using TaqMan assays. The relative 
levels of ERβ1 and ERβΔ5 variants were measured 
by assays designed to detect these transcripts at 
unique regions. The isoform ERβ1 was detected by 
assay to be located on the exon 7/8b junction (the 
population of transcripts with 8b exon is considered 
a wild-type isoform with intact ligand binding 
domain and AF-2 domain). Exon 5, ERβΔ5, was 
detected by an assay designed to cover the junction 
of coding exons 4 and 6.  
PATIENTS AND METHODS 
Sixty eight samples obtained after surgery from 
patients with primary breast tumors (adenocarcino-
mas) were analyzed. The patients all met the crite-
rium of primary operable unilateral invasive BC 
without previous treatment. All tumor samples 
were microdissected and only regions with more 
than 70 % of malignant epithelial cells were used for 
RNA isolation. Adjacent normal tissues were ob-
tained after total mastectomy from ten patients. 
Tissue was stored in liquid nitrogen until RNA and 
protein isolation. The study had received Institu-
tional Review Board approval according to the 
National Health Regulation and informed consent 
was obtained from all patients.  
Steroid receptors 
ER and PR were measured by a five-point dextrane-
coated charcoal assay in a cytosol fraction of frozen 
tumor tissue according to EORTC recommen-
dations (Eortc 1980).  
RNA Isolation and cDNA synthesis 
About 50 – 100 mg of frozen tissue (frozen in liquid 
nitrogen) was pulverized in a cold mortar vessel 
and extraction of the total RNA was performed by 
the acid-phenol guanidine method (Chomczynski 
1987). The quality of the RNA preparation was 
verified on agarose gels stained with ethidium 
bromide. Aliquots of the RNA samples used in real 
time analysis were treated with DNAse I (Fer-
mentas, Vilnius, Lithuania) and DNAse I was heat-
inactivated after treatment according to manufac-
turer instructions. Another phenol extraction was 
performed, followed by precipitation of the RNA. 
The RNA was dissolved again and its concentration 
was determined spectrophotometrically. One μg of 
the total RNA was reverse transcribed with 10 μM 
random hexamers and 1 μM oligo dT(15) primers 
in a 20 μl reaction volume using Omniscript RT Kit 
(Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions.  
Real-time PCR analysis 
All PCR reactions were performed using a Prism 
7000 Sequence Detection System (Applied 
Biosystems). PCR was carried out in a 25 μl reaction 
volume containing the 1x TaqMan Universal PCR 
Master Mix (Applied Biosystems), 1x TaqMan Pre-
Designed Gene Expression Assay specific for target 
transcript sequence and cDNA diluted with water 
(1:10). The TaqMan assays used for PCR were: 
Hs01100359_m1 for detection of the ERβ1 variant, 
and Hs01105521_m1 for ERβΔ5. The relative levels 
of ERβΔ5 in each sample were expressed as N-fold 
difference to (ERβ1) and splice variant (ERβΔ5) 
according to the equation: N = 2
-(CtERβ1 –CtERβΔ5) 
(Applied Biosystems, User Buletin#2, 2001), and 
relative to the calibrator, (sample with the highest 
difference value, lowest ERβΔ5 to ERβ1 ratio), 
according to the equation: N = 2
-(ΔCt sample – ΔCt calibrator).  
Validation experiment 
In order to check the amplification efficiency of the 
two assays (ERβ1 and ERβΔ5), serial dilutions of 
the sample were made and amplified by each of the 
assays (Applied Biosystems, User Buletin#2, 2001). 
The slopes of the curves obtained were calculated 
by the ABI Prism 7000 software. Results and Ct 
values were exported into MS Excel and ΔCt   ERΒΔ5 VARIANT IN BREAST CANCER  259 
Figure 1. Scatter plot showing the association of ERβΔ5 mRNA 
relative levels with the PR protein level in 67 samples of BC 
(Spearman, ρ= - 0,359, p=0.003). 
(average Ct β1 – average Ct β2Δ5) values were 
calculated for each dilution.  
Statistical analysis 
Nonparametric tests (Spearman, Mann-Whitney 
tests and Kruskal-Wallis Anova on Ranks) were 
used for the analysis of the correlation of the 
expression of ERβΔ5 with PR, and clinical and 
histopathological parameters.  
RESULTS 
The level of ERβΔ5 mRNA (splice variant) 
normalized to ERβ1 (full-length receptor) was 
calculated as N-fold difference in relation to the 
calibrator sample. The obtained value, which 
represents the assignment of Δ5 splice variant in the 
total ERβ1 transcript “pool”, was analyzed as a 
continuous variable for correlation with PR, and 
clinical and histopathological parameters. Before 
quantification, the experiment of validation was 
performed and reaction efficiency was determined 
for both assays. The resulting slopes were: -3.6328, 
for assay detecting the ERβ1, and -3.6811, for assay 
detecting the ERβΔ5; the resulting slope difference 
between the ERβ1(wt) and ERβΔ5 assay was 0.048, 
which suggests an acceptable difference in reaction 
efficiency. The expression of ERβ1 and ERβΔ5 
mRNAs was detected in all samples with lower Ct 
values for ERβ1 in all cases except one, where 
ERβΔ5 had the lower Ct value. This sample was 
excluded from the analysis.  
When analyzed as a continuous variable, the 
proportion of ERβΔ5 mRNA is associated with the 
PR protein level - these two variables are in inverse 
correlation (Spearman, ρ= -0.359, p=0.003) in the 
whole examined group of patients (Figure 1).  
There are no statistically significant differences 
in ERβΔ5 mRNA expression between groups of 
patients with different histopathological 
characteristics: IDC and ILC (invasive ductal and 
invasive lobular carcinoma), or within the groups 
defined by nodal status and tumor size. The 
correlation with tumor grade was not analyzed 
since most of the samples were of grade II. 
Although not significant, in this cohort we detected 
a trend (p=0.072, Mann-Whitney) towards higher 
ERβΔ5 mRNA expression in postmenopausal 
patients (median relative expression level 20.5, 42 
cases) compared to premenopausal ones (median 
relative expression level 11.2, 18 cases).  
Furthermore, we analyzed the expression level 
of ERβΔ5 in cancer samples in comparison with 
healthy mammary tissue. The median ERβΔ5 
mRNA expression in the samples of healthy 
mammary tissue was 35.3. We chose the arbitrary 
cut-off value of 20 to divide cancer samples into 
two groups. In 46% of the samples (31 out of 67) 
the ERβΔ5 mRNA relative levels were higher than 
20 – BC group I (median 35.7); in 54% of the 
analyzed samples (36 out of 67) the ERβΔ5 mRNA 
expression was lower than 20 – group II (median 
8.4). The levels of ERβΔ5 mRNAs in the group II 
breast cancers (less ERβΔ5 than in group I) 
significantly differs from the levels in healthy 
mammary tissue and group I (p < 0,05 Kruskal 
Wallis). In group I of breast cancer samples, the 
levels of ERβΔ5 mRNAs was in the range specific 
for healthy mammary tissue (Figure 2). 
In the BC group II (with less ERβΔ5 than in 
group I) the median level of PR protein was 260 VESNA  MANDUŠIĆ  ET AL. 
Figure 2. Two groups of BC defined according to ERβΔ5 
mRNA relative levels: BC-I – group with ratio > 20 of relative
expression units, and BC-II - group with ratio < 20 of relative
expression units. In the analyzed BC-I group of samples,
ERβΔ5 mRNA are in the range of those in normal breast tissue
(NB), but the BC-II group samples significantly differ from NB
(Kruskal Wallis, Dunn’s Method, p < 0.05). 
Figure 3. Box plots show different expression level of PR 
protein in BC I and BC II groups. 
significantly higher (14.5 fmol/mg total proteins of 
cytosol) than in the BC group I (5 fmol/mg total 
proteins), p=0,013, Mann-Whitney (Figure 3).  
DISCUSSION 
I n  t h i s  s t u d y ,  w e  p e r f o r m e d  t h e  s p e c i f i c  a n d  
sensitive TaqMan assay for qPCR to quantify the 
mRNAs of ERβΔ5 as a portion of the ERβ1 (wt 
isoform) total transcript pool. ERβΔ5 is a splice 
variant without the fifth exon of ERβ receptor.  
ERβΔ5 mRNA encodes truncated protein with-
out ligand binding domain and it poses dose depen-
dent inhibitory activity against the E2 stimulated 
transcriptional activity of ERα on ERE (Inoue 
2000). In spite of the fact that this variant is de-
tected in normal samples of breast tissue as well as 
in cancer samples, until now reports are scarce 
about this variant in clinical samples of BC (Poola 
2002b). In this study we normalized ERβΔ5 expres-
sion to the ERβ1 total transcript pool and obtained 
a value that represents the portion of this variant. 
Using this approach, it is not necessary to use the 
reference gene which is often differentially 
regulated in individuals, especially in tumors 
(Bustin 2000; Sabath 1990). In addition, searching 
for the appropriate reference gene is often time-
consuming and expensive, especially when a large 
number of samples are analyzed. Using this ap-
proach we showed that the relative levels of splice 
variant without the fifth exon were associated with 
the PR status. This effect may be a direct conse-
quence of the inhibitory activity of the variant 
protein on the full length ERα and ERβ trans-
cription from the PR promoter.  
To recapitulate, ERβΔ5 mRNA levels relative to 
ERβ1 were analyzed as a continuous variable and an 
inverse association was found with the PR protein 
level. The inverse association of ERβΔ5 PR ex-
pression may be a consequence of a decreased level 
of ERβΔ5 transcript rather than an increase of 
ERβ1, as we showed previously in a similar patient   ERΒΔ5 VARIANT IN BREAST CANCER  261 
Table 1. The clinical and histopathological characteristics of 
patients 
Parameter  Number of patients 
Age 
(mean: 57.8; range: 32 – 84) 
<45 
45-59 
>59 
 
 
12 
29 
27 
Menopausal status 
pre 
peri 
post 
unknown 
 
18 
6 
42 
2 
Histological type  
IDC 
ILC 
IDC+ILC 
other 
 
31 
23 
5 
9 
Histological grade 
I 
II 
III 
unknown 
 
3 
55 
6 
4 
ER  
ER (+)* 
ER (-) 
 
41 
27 
PR 
PR (+)** 
PR (-) 
 
21 
47 
Tumor size 
T1
§ 
T2+ T3
§ 
unknown 
 
31 
35 
2 
Nodal status 
N0 
N+(1-3) 
N+(≥4) 
unknown 
 
16 
25 
15 
12 
 
*ER-positive ≥ 10 and ER-negative < 10fmol/mg of total cytosol 
proteins; **PR-positive ≥ 20 and PR-negative< 20 fmol/mg of total 
cytosol proteins; 
§T1 ≤ 20mm; T2: 20-50mm; T3 ≥50mm. 
cohort by analyzing these two variants separately 
and using the normalization according to the β-
actin gene (Mandusic 2007). Consistent with our 
previous data, we suggest that the increased relative 
ratio of ERβ1 to ERβΔ5 is connected to the process 
of malignant transformation. The changed ratio of 
ERβ1/ERβΔ5 in approximately 50% of the cases 
mainly comes from a more pronounced decrease of 
ERβΔ5 mRNA than from ERβ1 mRNA in breast 
tumors compared to normal breast tissue (Man-
dusic 2006).  
The protein encoded by ERβΔ5 mRNA lacks C 
terminal domain (responsible for ligand binding), 
but has retained domains for nuclear localization 
and heterodimerization. Such a truncated receptor 
could potentially affect the transcriptional activities 
of both ERα and ERβ receptors. Using a cell 
transfection system, Inoue and coworkers showed , 
that the ERβΔ5 variant protein attenuates E2-
stimulated trans-activation by ERβ1 and ERα in a 
dose dependent manner (Inoue 2000). The 
inhibition of ERα transcriptional activity by the 
ERβΔ5 variant protein can cause a decrease in the 
PR protein level since it is ERα’s downstream target. 
This can be one of the sources of the ER+/PR-phe-
notype in breast cancers. Consequently, the ERβΔ5 
receptor may act as an inhibitor of transcriptional 
activity of wt isoforms of ERα (which leads to cell 
proliferation) and ERβ (whose activity suppresses 
proliferation) (Bardin 2004). The decrease of 
ERβΔ5 level may lead to a loss of inhibition of 
estrogen-stimulated proliferation via ERα. In this 
way, the ERβΔ5 splice variant may be involved in 
the progression of breast carcinogenesis.  
We suggest possible applications of this ap-
proach in future analyses of ER isoforms and splice 
variants in clinical samples of breast cancer. 
Although this approach was suggested previously, 
normalization of the splice variant to the wt recep-
tor is not exploited enough. It is proposed that nu-
merous isoforms of the estrogen receptor β, which 
differ in C terminal region, have different biological 
functions (Peng 2003). These isoforms are gene-
rated using the alternative eighth exon (Hirata 
2003) and can be easily analyzed as an RNA ratio in 
clinical studies on large number of samples without 
using the reference gene. Such an approach is cheap 
and not so time-consuming and may be useful for 
the analyzing of estrogen responsive tissues, where 262 VESNA  MANDUŠIĆ  ET AL. 
a subtle balance within the different isoforms of 
ERα and ERβ is crucial for the response to estrogen.  
In conclusion, we stress the necessity for ana-
lyzing the complete isoform and splice variants pro-
file of ERβ, as well as ERα and PR, in clinical sam-
ples, since it is possible that the pattern of isoform 
expression might be of prognostic and predictive 
value in clinical practice.  
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